Disc Medicine(IRON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IRON Disc Medicine

Market Closed 12-12 16:00:00 EST

91.85

-1.75

-1.87%

盘后91.53

-0.32-0.35%

17:56 EST

High94.51	Low91.52	Vol523.89K
Open92.95	D1 Closing93.60	Amplitude3.19%
Mkt Cap3.47B	Tradable Cap2.99B	Total Shares37.75M
T/O48.45M	T/O Rate1.61%	Tradable Shares32.58M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IRON","market":"US","secType":"STK","nameCN":"Disc Medicine","latestPrice":91.85,"timestamp":1765573200000,"preClose":93.6,"halted":0,"volume":523886,"hourTrading":{"tag":"盘后","latestPrice":91.53,"preClose":91.85,"latestTime":"17:56 EST","volume":19516,"amount":1792163.81,"timestamp":1765580182032},"delay":0,"floatShares":32580700,"shares":37750162,"eps":-5.424742,"marketStatus":"Market Closed","change":-1.75,"latestTime":"12-12 16:00:00 EST","open":92.95,"high":94.505,"low":91.52,"amount":48447835.208519995,"amplitude":0.031891,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.424742,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1597204800000,"exchange":"NASDAQ","adjPreClose":93.6,"preHourTrading":{"tag":"盘前","latestPrice":93.31,"preClose":93.6,"latestTime":"09:27 EST","volume":3,"amount":282.18,"timestamp":1765549670043},"postHourTrading":{"tag":"盘后","latestPrice":91.53,"preClose":91.85,"latestTime":"17:56 EST","volume":19516,"amount":1792163.81,"timestamp":1765580182032},"volumeRatio":1.179965412811548,"impliedVol":0.368,"impliedVolPercentile":0.008},"requestUrl":"/m/hq/s/IRON/tweets","defaultTab":"tweets","newsList":[{"id":"2590553966","title":"Press Release: LABRADOR IRON ORE ROYALTY CORPORATION - CASH DIVIDEND FOR THE FOURTH QUARTER OF 2025 - $0.35 PER COMMON SHARE","url":"https://stock-news.laohu8.com/highlight/detail?id=2590553966","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590553966?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:30","pubTimestamp":1765402200,"startTime":"0","endTime":"0","summary":"TORONTO, Dec. 10, 2025 /CNW/ - The Directors of Labrador Iron Ore Royalty Corporation   declared today a quarterly cash dividend of $0.35 per Common Share. The dividend is payable to holders of record at the close of business on December 31, 2025 and is to be paid on January 28, 2026.The Corporation holds a 15.10% equity interest in IOC directly and through its wholly-owned subsidiary, Hollinger-Hanna Limited, and receives a 7% gross overriding royalty on all iron ore products produced, sold and shipped by IOC and a 10 cent per tonne commission on all iron ore products produced and sold by IOC.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FOR","CASH","BK4139","BK4211","IRON","BK4024","LU0053671581.USD"],"gpt_icon":0},{"id":"2590137985","title":"Disc Medicine (IRON): Reassessing Valuation After Encouraging RALLY-MF Phase 2 Anemia Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2590137985","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590137985?lang=en_us&edition=fundamental","pubTime":"2025-12-10 04:18","pubTimestamp":1765311522,"startTime":"0","endTime":"0","summary":"Early Trial Data Puts Disc Medicine In Focus\nDisc Medicine (IRON) just put its RALLY-MF Phase 2 data for DISC-0974 on the table, showing meaningful anemia improvements in myelofibrosis patients that could reshape expectations around this small hematology focused pipeline.\nSee our latest analysis for Disc Medicine.\nThe news lands with Disc already in a strong groove, with a roughly 53% 3 month share price return and a 42.65% 1 year total shareholder return hinting that momentum is building...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/news/disc-medicine-iron-reassessing-valuation-after-encouraging-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/news/disc-medicine-iron-reassessing-valuation-after-encouraging-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","LU0053671581.USD","BK4139","IRON"],"gpt_icon":0},{"id":"2589825187","title":"Disc Medicine Reports Positive Phase 2 Trial Results for DISC-0974 in Myelofibrosis-Related Anemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2589825187","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589825187?lang=en_us&edition=fundamental","pubTime":"2025-12-06 21:00","pubTimestamp":1765026014,"startTime":"0","endTime":"0","summary":"Disc Medicine Inc. announced positive initial data from the Phase 2 RALLY-MF clinical trial evaluating DISC-0974 for the treatment of anemia in patients with myelofibrosis. Results were presented at the 67th American Society of Hematology  Annual Meeting. The data showed that DISC-0974 led to substantial reductions in hepcidin and increased iron levels, resulting in clinically meaningful improvements in anemia across various patient groups, regardless of baseline transfusion status or concomitant JAK inhibitor therapy. The treatment was generally well-tolerated, with diarrhea and urinary tract infections being the only adverse events considered related to DISC-0974 and reported in two or more subjects. Additional data from the study are expected to be shared in the second half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nNDL9GHNxm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B3QW5Z07.USD","BK4139","IRON","LU0314104364.USD","IE00BGHQF748.EUR","SG9999014013.SGD","LU0053671581.USD","LU2210149790.SGD","LU2095319765.USD","SG9999014005.SGD","BK4585","IE00BKPKM429.USD","BK4112","SG9999014021.USD","BK4588","IE00B64PRP62.GBP","NDAQ"],"gpt_icon":0},{"id":"2589913825","title":"Disc Medicine Presents Positive Initial Data From Rally-Mf Phase 2 Trial in Patients With Myelofibrosis (Mf) and Anemia at the 67TH American Society of Hematology (Ash) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2589913825","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589913825?lang=en_us&edition=fundamental","pubTime":"2025-12-06 21:00","pubTimestamp":1765026002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nTUA4R7QQG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0053671581.USD","BK4139","IRON"],"gpt_icon":0},{"id":"2587273643","title":"Disc Medicine Inc : Jefferies Raises Target Price to $154 From $127","url":"https://stock-news.laohu8.com/highlight/detail?id=2587273643","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587273643?lang=en_us&edition=fundamental","pubTime":"2025-11-29 00:03","pubTimestamp":1764345786,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40FO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRON","BK4139","LU0053671581.USD"],"gpt_icon":0},{"id":"2584101069","title":"Disc Medicine’s Growth Potential Driven by Innovative Treatments and Promising Market Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2584101069","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584101069?lang=en_us&edition=fundamental","pubTime":"2025-11-19 18:45","pubTimestamp":1763549120,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tara Bancroft has maintained their bullish stance on IRON stock, giving a Buy rating on November 14. Tara Bancroft’s rating is bas...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/disc-medicines-growth-potential-driven-by-innovative-treatments-and-promising-market-opportunities-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/disc-medicines-growth-potential-driven-by-innovative-treatments-and-promising-market-opportunities-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IRON","LU0053671581.USD"],"gpt_icon":0},{"id":"2584569269","title":"XPeng CEO Plays The Anti-Tesla Card: While Optimus Is Closed, IRON Goes Open Source","url":"https://stock-news.laohu8.com/highlight/detail?id=2584569269","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584569269?lang=en_us&edition=fundamental","pubTime":"2025-11-18 22:49","pubTimestamp":1763477340,"startTime":"0","endTime":"0","summary":"XPeng (XPEV) takes open approach with IRON (while Tesla's Optimus remains proprietary) allowing developers to train and build on it.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/18/Robots-at-work.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/18/Robots-at-work.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/tech/25/11/48924043/xpeng-ceo-plays-the-anti-tesla-card-while-optimus-is-closed-iron-goes-open-source","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/tech/25/11/48924043/xpeng-ceo-plays-the-anti-tesla-card-while-optimus-is-closed-iron-goes-open-source","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU2602419157.SGD","LU0210536198.USD","BK4574","IE00B1BXHZ80.USD","IE00BSNM7G36.USD","LU0053671581.USD","LU0708995401.HKD","BK4533","LU0820561909.HKD","BK4592","LU0672654240.SGD","LU1778281490.HKD","LU1066051811.HKD","TSYW.SI","IE00B19Z9505.USD","LU1066053197.SGD","LU0109391861.USD","LU0056508442.USD","LU2063271972.USD","TSLA","LU1551013425.SGD","LU2417539215.USD","LU2750360997.AUD","LU1429558221.USD","BK4099","IE00BK4W5M84.HKD","BK4588","LU1720051017.SGD","EVS.SI","LU0234570918.USD","LU1232071149.USD","LU2756315318.SGD","LU0820561818.USD","XPEV","LU1435385759.SGD","TSLL","BK4543","BK4581","LU1674673691.USD","LU2420271590.USD","IRON","LU2213496289.HKD","LU1066051225.USD","LU2087621335.USD","LU0719512351.SGD","LU2290526834.HKD","LU1629891620.HKD","BK4511","BK4612","BK4534"],"gpt_icon":1},{"id":"2584936386","title":"Tesla Rival Xpeng To Release 3 Robotaxi Models, Says Technology Does Not Depend On LiDAR — Optimus Rival IRON Could Be A 'Tour Guide'","url":"https://stock-news.laohu8.com/highlight/detail?id=2584936386","media":"Benzinga_recent_news","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584936386?lang=en_us&edition=fundamental","pubTime":"2025-11-18 18:19","pubTimestamp":1763461140,"startTime":"0","endTime":"0","summary":"Xpeng plans to launch 3 new Robotaxi models in 2026, offer licensing opportunities, and use humanoid robot 'IRON' as a tour guide.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/18/Xpeng.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/18/Xpeng.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/tech/25/11/48917970/tesla-rival-xpeng-to-release-3-robotaxi-models-says-technology-does-not-depend-on-lidar-optimus-rival-iron-could-be-a-tour-guide","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/tech/25/11/48917970/tesla-rival-xpeng-to-release-3-robotaxi-models-says-technology-does-not-depend-on-lidar-optimus-rival-iron-could-be-a-tour-guide","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4516","LU0820561909.HKD","LU2108987350.USD","LU2417539215.USD","IE00B1BXHZ80.USD","LU0949170772.SGD","LU2236285917.USD","LU0198837287.USD","LU1267930730.SGD","LU0821914370.USD","LU0345770993.USD","BK4538","LU0738911758.USD","LU1674673428.USD","LU2249611893.SGD","BK4604","TSYW.SI","LU0943347566.SGD","IRON","TSLL","LU1769817096.USD","LU0320765059.SGD","LU0553294199.USD","LU2360107168.USD","LU1720051017.SGD","LU1778281490.HKD","XPEV","BK4607","LU0820562030.AUD","EVS.SI","LU1046421795.USD","LU0234572021.USD","LU0348723411.USD","LU2148611432.USD","LU0053671581.USD","LU0348816934.USD","LU2213496289.HKD","LU0109391861.USD","LU0823411888.USD","ALBmain","BK4554","BK4527","LU0097036916.USD","LU1720051108.HKD","BK4534","BK4598","IE00B19Z9505.USD"],"gpt_icon":1},{"id":"2584169861","title":"Why Disc Medicine (IRON) Is Up 7.3% After FDA Priority Review and $250M Capital Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2584169861","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584169861?lang=en_us&edition=fundamental","pubTime":"2025-11-16 23:16","pubTimestamp":1763306196,"startTime":"0","endTime":"0","summary":"In the past week, Disc Medicine announced the initiation of a Phase 1b clinical trial for DISC-3405 in adults with sickle cell disease and reported the FDA's priority review of its New Drug Application for bitopertin in erythropoietic protoporphyria, alongside a public offering of approximately US$250 million in support of commercialization and R&D.\nA key insight is that these clinical and regulatory advances highlight Disc Medicine’s emphasis on expanding its pipeline for hematological...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/news/why-disc-medicine-iron-is-up-73-after-fda-priority-review-an","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/news/why-disc-medicine-iron-is-up-73-after-fda-priority-review-an","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IRON","LU0053671581.USD","BK4139"],"gpt_icon":0},{"id":"2583680034","title":"H.C. Wainwright Remains a Buy on Disc Medicine (IRON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583680034","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583680034?lang=en_us&edition=fundamental","pubTime":"2025-11-15 07:38","pubTimestamp":1763163496,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Disc Medicine today and set a price target of $118.00. Tsao covers the Healthcare s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-disc-medicine-iron-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-disc-medicine-iron-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRON","BK4588","XBI","LABU","BK4581","BK4585","BK4139","XLV"],"gpt_icon":0},{"id":"2583417325","title":"Disc Medicine COO Jonathan Yen-Wen Yu Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583417325","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583417325?lang=en_us&edition=fundamental","pubTime":"2025-11-14 09:23","pubTimestamp":1763083386,"startTime":"0","endTime":"0","summary":"Jonathan Yen-Wen Yu, Chief Operating Officer of Disc Medicine Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 13, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL7XXn9D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Disc Medicine COO Jonathan Yen-Wen Yu Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRON","BK4139"],"gpt_icon":0},{"id":"2582805669","title":"Disc Medicine Is Maintained at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2582805669","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582805669?lang=en_us&edition=fundamental","pubTime":"2025-11-11 00:34","pubTimestamp":1762792440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRON/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 11:34 ET (16:34 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRON"],"gpt_icon":0},{"id":"2582191870","title":"Disc Medicine price target raised to $114 from $86 at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2582191870","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582191870?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:55","pubTimestamp":1762786555,"startTime":"0","endTime":"0","summary":"Truist raised the firm’s price target on Disc Medicine (IRON) to $114 from $86 and keeps a Buy rating on the shares. The firm is updating its model...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/disc-medicine-price-target-raised-to-114-from-86-at-truist-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/disc-medicine-price-target-raised-to-114-from-86-at-truist-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRON"],"gpt_icon":0},{"id":"2582874547","title":"Truist Financial Sticks to Their Buy Rating for Disc Medicine (IRON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582874547","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582874547?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:25","pubTimestamp":1762781144,"startTime":"0","endTime":"0","summary":"In a report released today, Danielle Brill from Truist Financial maintained a Buy rating on Disc Medicine, with a price target of $114.00. Accordin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-their-buy-rating-for-disc-medicine-iron-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-their-buy-rating-for-disc-medicine-iron-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRON"],"gpt_icon":0},{"id":"2581747852","title":"Disc Medicine (IRON): A Fresh Look at Valuation Following Key FDA Milestone and Pipeline Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2581747852","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581747852?lang=en_us&edition=fundamental","pubTime":"2025-11-08 16:35","pubTimestamp":1762590953,"startTime":"0","endTime":"0","summary":"Disc Medicine (IRON) has been in the spotlight after submitting a New Drug Application for bitopertin, earning an FDA National Priority Voucher, and unveiling early trial data in several blood disorders. These moves highlight growing pipeline momentum and increasing investor interest.\nSee our latest analysis for Disc Medicine.\nDisc Medicine's momentum has translated into a remarkable 44.5% share price return over the last three months and a 19.3% gain for the past month, even with some...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/news/disc-medicine-iron-a-fresh-look-at-valuation-following-key-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/news/disc-medicine-iron-a-fresh-look-at-valuation-following-key-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IRON","BK4139","DCF"],"gpt_icon":0},{"id":"2581885776","title":"Disc Medicine: Strong Financial Position and Promising Product Pipeline with Bitopertin’s Billion-Dollar Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2581885776","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581885776?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:56","pubTimestamp":1762523814,"startTime":"0","endTime":"0","summary":"Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Disc Medicine. The associated price target remains the same with $110....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/disc-medicine-strong-financial-position-and-promising-product-pipeline-with-bitopertins-billion-dollar-potential-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/disc-medicine-strong-financial-position-and-promising-product-pipeline-with-bitopertins-billion-dollar-potential-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IRON"],"gpt_icon":0},{"id":"2581043755","title":"Disc Medicine’s Promising Pipeline and Regulatory Advancements Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2581043755","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581043755?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:35","pubTimestamp":1762464941,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tara Bancroft has maintained their bullish stance on IRON stock, giving a Buy rating on November 3. Tara Bancroft’s rating is base...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/disc-medicines-promising-pipeline-and-regulatory-advancements-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/disc-medicines-promising-pipeline-and-regulatory-advancements-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRON"],"gpt_icon":0},{"id":"2581099349","title":"Earnings Flash (IRON) Disc Medicine Posts Q3 Net Loss $1.77 a Share, vs. FactSet Est of $1.44 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2581099349","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581099349?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:46","pubTimestamp":1762436773,"startTime":"0","endTime":"0","summary":"Earnings Flash (IRON) Disc Medicine Posts Q3 Net Loss $1.77 a Share, vs. FactSet Est of $1.44 Loss","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IRON"],"gpt_icon":0},{"id":"2581964340","title":"Biopharma firm Disc Medicine's Q3 net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2581964340","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581964340?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:40","pubTimestamp":1762436444,"startTime":"0","endTime":"0","summary":"Biopharma firm Disc Medicine's Q3 net loss widensOverviewDisc Medicine Q3 net loss and EPS miss analyst expectationsCompany submitted NDA for bitopertin, received priority review voucherDisc Medicine'","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0T7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRON","BK4139"],"gpt_icon":0},{"id":"2581961450","title":"Disc Medicine Q3 EPS $(1.77) Misses $(1.51) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581961450","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581961450?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:40","pubTimestamp":1762436436,"startTime":"0","endTime":"0","summary":"Disc Medicine (NASDAQ:IRON) reported quarterly losses of $(1.77) per share which missed the analyst consensus estimate of $(1.51) by 16.91 percent. This is a 98.88 percent decrease over losses of $(0.89) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48685158/disc-medicine-q3-eps-1-77-misses-1-51-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRON"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.discmedicine.com","stockEarnings":[{"period":"1week","weight":-0.0151},{"period":"1month","weight":0.0678},{"period":"3month","weight":0.5354},{"period":"6month","weight":0.7101},{"period":"1year","weight":0.4291},{"period":"ytd","weight":0.4487}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Disc Medicine Opco Inc, together with its subsidiaries, operates as a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company builds a portfolio of fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. It also develops bitopertin for the treatment of erythropoietic porphyrias, erythropoietic protoporphyria, and X-linked protoporphyria. In addition, the company develops DISC-0974 for the treatment of chronic kidney disease; MWTX-003 for the treatment of polycythemia vera, and other hematologic disorders; and DISC-0998 for the treatment of anemia associated with inflammatory. The company is based in Watertown, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.025839},{"month":2,"riseRate":0.8,"avgChangeRate":0.03392},{"month":3,"riseRate":0.2,"avgChangeRate":-0.08973},{"month":4,"riseRate":0.4,"avgChangeRate":-0.012723},{"month":5,"riseRate":0.6,"avgChangeRate":0.039664},{"month":6,"riseRate":0.8,"avgChangeRate":0.10084},{"month":7,"riseRate":0.4,"avgChangeRate":-0.052496},{"month":8,"riseRate":0.8,"avgChangeRate":0.093002},{"month":9,"riseRate":0.5,"avgChangeRate":-0.006486},{"month":10,"riseRate":0.333333,"avgChangeRate":0.020523},{"month":11,"riseRate":0.666667,"avgChangeRate":0.064648},{"month":12,"riseRate":0.666667,"avgChangeRate":0.056208}],"exchange":"NASDAQ","name":"Disc Medicine","nameEN":"Disc Medicine"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Disc Medicine(IRON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Disc Medicine(IRON) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Disc Medicine,IRON,Disc Medicine股票,Disc Medicine股票老虎,Disc Medicine股票老虎国际,Disc Medicine行情,Disc Medicine股票行情,Disc Medicine股价,Disc Medicine股市,Disc Medicine股票价格,Disc Medicine股票交易,Disc Medicine股票购买,Disc Medicine股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Disc Medicine(IRON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Disc Medicine(IRON) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction